VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.640
+0.001 (0.22%)
At close: Apr 28, 2026, 4:00 PM EDT
0.622
-0.018 (-2.80%)
After-hours: Apr 28, 2026, 6:45 PM EDT
VYNE Therapeutics Employees
VYNE Therapeutics had 10 employees as of December 31, 2025. The number of employees decreased by 3 or -23.08% compared to the previous year.
Employees
10
Change (1Y)
-3
Growth (1Y)
-23.08%
Revenue / Employee
$57,000
Profits / Employee
-$2,648,300
Market Cap
21.32M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Quince Therapeutics | 38 |
| OSR Holdings | 22 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| NewcelX | 15 |
| Cocrystal Pharma | 10 |
| Allarity Therapeutics | 8 |
VYNE News
- 4 months ago - VYNE Therapeutics Transcript: M&A Announcement - Transcripts
- 4 months ago - VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement - GlobeNewsWire
- 6 months ago - VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo - GlobeNewsWire
- 10 months ago - VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - GlobeNewsWire
- 1 year ago - VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga